Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.33 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13990322 | 0.82 | RAPGEF4 (0.36) | NOTUMP2RX7IDO1RAPGEF4PDE2A | |
| SCHEMBL9889139 | 0.77 | NOTUM (0.38) | NOTUM | |
| SCHEMBL805462 | 0.75 | P2RX7 (0.42) | NOTUMP2RX7PDE2A | |
| SCHEMBL30524329 | 0.75 | NOTUM (0.41) | NOTUMP2RX7IDO1RAPGEF4HTR3E | |
| SCHEMBL2991016 | 0.75 | NOTUM (0.41) | NOTUMP2RX7IDO1RAPGEF4HTR3E | |
| SCHEMBL23138933 | 0.74 | NOTUM (0.33) | NOTUM | |
| SCHEMBL10493634 | 0.74 | AR (0.40) | NOTUMP2RX7IDO1RAPGEF4HTR3E | |
| SCHEMBL24946313 | 0.73 | CSNK2A2 (0.38) | NOTUMP2RX7CLCN2AR | |
| SCHEMBL15850524 | 0.73 | NOTUM (0.61) | NOTUMP2RX7HTR3ACLCN2 | |
| SCHEMBL1263960 | 0.73 | NOTUM (0.50) | NOTUMIDO1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021457-B2 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-06-01 | — | — | US | disclosed |
| US-20210106568-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20200071291-A1 | A CLASS OF ISOINDOLONE-IMIDE RING-1,3-DIONE-2-ENE COMPOUNDS, COMPOSITION AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-03-05 | — | — | US | disclosed |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | NOTUM 2397/4885P2RX7 124/4885IDO1 1142/4885 |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | NOTUM 2255/4885P2RX7 96/4885IDO1 573/4885 |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | NOTUM 2255/4885P2RX7 96/4885IDO1 573/4885 |
| US-20200071291-A1 | A CLASS OF ISOINDOLONE-IMIDE RING-1,3-DIONE-2-ENE COMPOUNDS, COMPOSITION AND USE THEREOF | ATG7, MLST8, BECN1 | NOTUM 4665/4885P2RX7 1541/4885IDO1 139/4885 |
| US-11021457-B2 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | ATG7, MLST8, BECN1 | NOTUM 4653/4885P2RX7 1701/4885IDO1 115/4885 |
| US-20210106568-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | NOTUM 2397/4885P2RX7 124/4885IDO1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.